Treating liver cancer tumors to shrink them in order to allow the patient to qualify for a liver transplant leads to excellent 10-year post-transplant outcomes, according to new Mount Sinai research published in JAMA Surgery. ...
Jul 22, 2022
0
69
Experts from Cedars-Sinai Cancer have analyzed patient samples, along with studies conducted in animal models, to identify a novel immune checkpoint pathway to treat hepatocellular carcinoma, the most common form of liver ...
Jun 20, 2022
0
108
China has the highest morbidity of hepatocellular carcinoma (HCC) in the world. For HCC patients in early stage disease, surgical resection is the best treatment strategy, but most patients in advanced stages lose the opportunity ...
Jun 15, 2022
0
7
For patients with unresectable very early to early-stage hepatocellular carcinoma with suboptimal location for ablation, radiation segmentectomy is efficacious with few high-grade adverse events, according to a study published ...
Jun 6, 2022
0
6
A team of researchers from the College of Design and Engineering, the N.1 Institute for Health and the Cancer Science Institute of Singapore at the National University of Singapore has recently engineered in vitro tumor models ...
Jun 2, 2022
0
33
New research from Baylor College of Medicine and Texas Children's Cancer Center characterizes a new molecular type of high-risk pediatric liver cancer. The study, published in the Journal of Hepatology, showed that these ...
May 18, 2022
0
23
In recent years, the immunotherapy field has revolutionized oncology treatment methods by developing therapeutics that help a cancer patient's own immune system fight their disease. However, these treatments have had varied ...
May 16, 2022
0
4
A study led by Xiujun Cai (Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine) screened the whole genome of hepatocellular carcinoma cells (HepG2) through CRISPR / cas9 system ...
Apr 19, 2022
0
2
Hepatocellular carcinoma (HCC) is the most primary liver cancer. It is one of the most common and deadly cancer worldwide, especially in East Asia. Advanced HCC patients expect a significantly low 5-year survival rate as ...
Apr 18, 2022
0
2
Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.
Apr 13, 2022
0
62
